VERU INC.
VERU INC. (VERU): 3 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
9.9 months
D/E 0.24 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~286d
N/A
A transparent, data-derived signal for VERU INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$50.2M
Cash
$27.6M
Quarterly Burn
$8.9M
Runway
9.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| enobosarm | Phase 2 |
| sabizabulin | Phase 3 |
| semaglutide weekly | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$7.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,078,764 | $2.4M |
| alyeska investment group, l.p. | 1,000,000 | $2.2M |
| oppenheimer & co inc | 196,300 | $434K |
| geode capital management, llc | 184,622 | $408K |
| millennium management llc | 150,401 | $332K |
| blackrock, inc. | 114,169 | $252K |
| citadel advisors llc | 81,882 | $181K |
| vanguard fiduciary trust co | 80,653 | $178K |
| choreo, llc | 75,263 | $166K |
| renaissance technologies llc | 69,250 | $153K |
Showing top 10 of 55 institutional holders of VERU INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in VERU INC.'s pipeline?
VERU INC. (VERU) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is VERU INC.'s lead drug candidate?
VERU INC.'s most advanced tracked candidate is enobosarm (Phase 2) for Muscle Loss; Obesity & Overweight.
What is VERU INC.'s next catalyst?
VERU INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: enobosarm + semaglutide" — expected March 31, 2027.
What is VERU INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, VERU INC. has approximately 9.9 months of cash runway.
What is VERU INC.'s market capitalization?
VERU INC.'s market capitalization is approximately $50.2M.
Get the full picture on VERU INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.